Bristol-Myers Squibb and AstraZeneca have announced that investigational diabetes drug dapagliflozin has met the endpoints of a 24-week Phase III study involving 597 patients.

The selective SGLT2 inhibitor produced significant reductions in glycosylated haemoglobin levels in type 2 diabetic patients when added to another diabetes drug.

The drug also met its secondary efficacy endpoints of reducing total body weight, oral glucose tolerance and fasting plasma glucose levels from baseline at week 24.

There are currently 20 SGLT2 inhibitors under development, with Johnson & Johnson’s canagliflozin also in early Phase III trials.